The New England Journal of Medicine Publishes Results of Final Landmark Phase III Efficacy Clinical Study of Sanofi Pasteur’s Dengue Vaccine Candidate

Study successfully met primary objective and confirms high efficacy against severe dengue and hospitalization Sanofi Pasteur intends to file for registration in several endemic countries in 2015 Dengue vaccine candidate would address an urgent unmet medical need in tropical and sub-tropical regions of the world November 3, 2014 Sanofi Pasteur, the vaccines division of Sanofi, today announced the publication of …

Sanofi’s Dengue Vaccine To Market in 2015

Sanofi Pasteur announces a successfull phase III trial in Latin America and plans to enter the market in 2015 The vaccines division of Sanofi  has published the results of their second phase III trial of their dengue vaccine candidate. The study, published in The New England Journal of Medicine, looked at the efficacy of the vaccine in Latin America, and …

Sanofi Pasteur Introduces 4-Strain Influenza Vaccine (Fluzone) in Canada

New standard of care for the prevention of influenza A 4-strain influenza vaccine for individuals six months of age and older Helps protect children and adults against an additional influenza B strain October 1, 2014 Sanofi Pasteur, the vaccines division of Sanofi, is pleased to announce the launch of its 4-strain influenza vaccine (Fluzone® Quadrivalent) in Canada. This new vaccine was introduced …

FDA Approves Use of Menactra® Vaccine for Booster Immunization Against Potentially Deadly Disease

Approval aligns with Centers for Disease Control and Prevention’s recommendations for meningococcal vaccination September 11, 2014 Sanofi Pasteur, the vaccines division of Sanofi , announced today that the U.S. Food and Drug Administration (FDA) approved use of Menactra® [Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine] for booster vaccination against meningococcal disease in persons 15 years …

New Positive Dengue Vaccine Results From Sanofi’s Biggest Trial Yet

Sanofi today announced the positive results of a 20,000 strong phase III trial of their pioneering dengue vaccine This final study from Sanofi Pasteur, Sanofi’s vaccine arm, has demonstrated a 60.8 reduction in cases of dengue  fever amongst it’s 20,875 strong population of 9-16 year olds in Latin America. This was accompanied by a 80% reduction in hospitalisations caused by …

Sanofi Pasteur’s Dengue vaccine Candidate Successfully Completes Final Landmark Phase III Clinical Efficacy Study in Latin America

Second, large-scale phase III study successfully meets primary endpoint with overall vaccine efficacy of 60.8 percent and shows efficacy against each of the four dengue serotypes – Additional observation of the results shows a significant reduction of the risk of hospitalization by 80.3 percent confirming the potential public health impact of the vaccine Initial safety data are consistent with the …

Sanofi Pasteur Announces Publication of Positive Data for Fluzone High-Dose Vaccine in the New England Journal of Medicine

Study Demonstrates Fluzone High-Dose Vaccine 24.2 Percent More Effective Than Standard-Dose Fluzone Vaccine in Preventing Influenza in Adults 65 Years of Age and Older August 13, 2014 Sanofi Pasteur, the vaccines division of Sanofi, today announced that The New England Journal of Medicine published positive results from a large-scale, multi-center efficacy trial, which found that Fluzone® High-Dose (Influenza Vaccine) was …

Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine For Upcoming 2014-2015 Season In United States

Largest U.S. influenza vaccine supplier, providing broad product portfolio, will distribute at least 65 million doses to help protect people across multiple age groups against the virus this season July 22, 2014 Sanofi Pasteur, the vaccines division of Sanofi, announced today that the first lots of Fluzone® (Influenza Vaccine) for the 2014-2015 influenza (“the flu”) season have been released by the …